Sunder Biomedical Tech. Co., Ltd.
Sunder Biomedical Tech. Co., Ltd. engages in the manufacture and sale of medical devices. It offers endoscopy vision set, suction irrigation set, smoke filter, endo bag, blood line set for hemodialysis, A.V. fistula needle, I.V. administration, volume control I.V. administration, extension tube. surgical tubing set, PVC compounds for medical application, transducer protector, melt blown nonwoven … Read more
Sunder Biomedical Tech. Co., Ltd. (4115) - Net Assets
Latest net assets as of June 2025: NT$730.10 Million TWD
Based on the latest financial reports, Sunder Biomedical Tech. Co., Ltd. (4115) has net assets worth NT$730.10 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.21 Billion) and total liabilities (NT$475.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$730.10 Million |
| % of Total Assets | 60.56% |
| Annual Growth Rate | 0.72% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.74 |
Sunder Biomedical Tech. Co., Ltd. - Net Assets Trend (2020–2024)
This chart illustrates how Sunder Biomedical Tech. Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sunder Biomedical Tech. Co., Ltd. (2020–2024)
The table below shows the annual net assets of Sunder Biomedical Tech. Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$777.43 Million | +5.64% |
| 2023-12-31 | NT$735.89 Million | -6.90% |
| 2022-12-31 | NT$790.45 Million | -2.29% |
| 2021-12-31 | NT$809.01 Million | +7.09% |
| 2020-12-31 | NT$755.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sunder Biomedical Tech. Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$41.24 Million | 5.30% |
| Common Stock | NT$600.00 Million | 77.18% |
| Other Components | NT$136.19 Million | 17.52% |
| Total Equity | NT$777.43 Million | 100.00% |
Sunder Biomedical Tech. Co., Ltd. Competitors by Market Cap
The table below lists competitors of Sunder Biomedical Tech. Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asia Pacific Investment JSC
VN:API
|
$2.11K |
|
American Noble Gas Inc.
OTCQB:AMNI
|
$2.11K |
|
Linklogis Inc. Class B
F:0NY
|
$2.11K |
|
Traction Uranium Corp.
OTCQB:TRCTD
|
$2.11K |
|
BC IRON (BC3.SG)
STU:BC3
|
$2.11K |
|
Bela Automotive Limited
KAR:BELA
|
$2.11K |
|
Egyptian Real Estate Group Bearer Shares
EGX:AREHA
|
$2.10K |
|
CMDKF
PINK:CMDKF
|
$2.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sunder Biomedical Tech. Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 735,888,000 to 777,428,000, a change of 41,540,000 (5.6%).
- Net income of 29,097,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 19,442,000.
- Other factors increased equity by 31,885,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$29.10 Million | +3.74% |
| Other Comprehensive Income | NT$-19.44 Million | -2.5% |
| Other Changes | NT$31.89 Million | +4.1% |
| Total Change | NT$- | 5.64% |
Book Value vs Market Value Analysis
This analysis compares Sunder Biomedical Tech. Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$12.56 | NT$7.10 | x |
| 2021-12-31 | NT$13.45 | NT$7.10 | x |
| 2022-12-31 | NT$13.16 | NT$7.10 | x |
| 2023-12-31 | NT$12.26 | NT$7.10 | x |
| 2024-12-31 | NT$12.95 | NT$7.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sunder Biomedical Tech. Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.79%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.69x
- Recent ROE (3.74%) is above the historical average (3.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 6.96% | 5.77% | 0.60x | 2.00x | NT$-22.97 Million |
| 2021 | 8.78% | 6.24% | 0.74x | 1.89x | NT$-9.85 Million |
| 2022 | 1.68% | 1.26% | 0.74x | 1.80x | NT$-65.73 Million |
| 2023 | -4.51% | -4.30% | 0.55x | 1.91x | NT$-106.74 Million |
| 2024 | 3.74% | 3.79% | 0.58x | 1.69x | NT$-48.65 Million |
Industry Comparison
This section compares Sunder Biomedical Tech. Co., Ltd.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,907,891,111
- Average return on equity (ROE) among peers: 11.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sunder Biomedical Tech. Co., Ltd. (4115) | NT$730.10 Million | 6.96% | 0.65x | $2.11K |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Nang Kuang Pharmaceutical Co Ltd (1752) | $2.19 Billion | 9.94% | 0.50x | $46.91 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $53.63 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.95 Million |
| Bioteque (4107) | $1.88 Billion | 15.46% | 0.25x | $198.92 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $41.85 Million |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |